{"id":"l-amb-standard-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (elevated creatinine)"},{"rate":null,"effect":"Infusion-related reactions (fever, chills, rigors)"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hypomagnesemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:43:49.813913","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amphotericin B is a polyene antifungal that preferentially targets ergosterol, a sterol unique to fungal membranes, rather than cholesterol in human cells. The drug inserts into the fungal membrane and forms ion channels, causing leakage of intracellular contents and fungal cell lysis. The liposomal formulation reduces nephrotoxicity by preferentially delivering the drug to fungal cells and infected tissues.","oneSentence":"L-AmB (liposomal amphotericin B) binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and lead to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:07.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive fungal infections (candidiasis, aspergillosis, cryptococcosis)"},{"name":"Empiric therapy for suspected fungal infections in immunocompromised patients"}]},"_fixedFields":["pubmed(14)"],"trialDetails":[{"nctId":"NCT07369856","phase":"NA","title":"Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure","status":"RECRUITING","sponsor":"Cardiology Research UBC","startDate":"2025-11-04","conditions":"Heart Failure, Diuretics","enrollment":300},{"nctId":"NCT07300553","phase":"PHASE2","title":"Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-02","conditions":"IBD, Crohn Disease, Ulcerative Colitis (UC)","enrollment":45},{"nctId":"NCT07261150","phase":"PHASE3","title":"Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-05-01","conditions":"Histoplasmosis","enrollment":664},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT05101187","phase":"PHASE3","title":"Olorofim Aspergillus Infection Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"F2G Biotech GmbH","startDate":"2022-03-31","conditions":"Invasive Aspergillosis","enrollment":225},{"nctId":"NCT05593666","phase":"PHASE2","title":"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Drugs for Neglected Diseases","startDate":"2022-12-27","conditions":"Primary Visceral Leishmaniasis","enrollment":101},{"nctId":"NCT05113641","phase":"NA","title":"Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)","status":"RECRUITING","sponsor":"Dylan MacKay","startDate":"2023-08-04","conditions":"Chronic Kidney Diseases, Metabolic Acidosis","enrollment":40},{"nctId":"NCT07191756","phase":"","title":"Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qiu Ye","startDate":"2025-05-15","conditions":"Mucormycosis","enrollment":150},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT04157465","phase":"NA","title":"Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-11-07","conditions":"Antifungal Agents, Invasive Fungal Infections, Mycoses","enrollment":216},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":"HIV/AIDS-associated Talaromycosis","enrollment":116},{"nctId":"NCT05865743","phase":"PHASE3","title":"Perioperative SDD to Prevent Infectious Complications After Esophagectomy","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-10-21","conditions":"Esophageal Cancer","enrollment":854},{"nctId":"NCT05814432","phase":"PHASE3","title":"Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS","status":"RECRUITING","sponsor":"Federal University of Health Science of Porto Alegre","startDate":"2025-01-16","conditions":"Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression","enrollment":279},{"nctId":"NCT05468372","phase":"PHASE2","title":"Amphotericin Versus Posaconazole for Pulmonary Mucormycosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-07-01","conditions":"Mucormycosis; Pulmonary (Etiology)","enrollment":50},{"nctId":"NCT04799236","phase":"PHASE3","title":"Treatment of Mucosal Bolivian Leishmaniasis","status":"RECRUITING","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2021-04-01","conditions":"Mucosal Leishmaniasis","enrollment":120},{"nctId":"NCT03945448","phase":"PHASE2, PHASE3","title":"Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia","status":"RECRUITING","sponsor":"Makerere University","startDate":"2019-06-20","conditions":"Cryptococcal Meningitis","enrollment":356},{"nctId":"NCT04031833","phase":"PHASE1, PHASE2","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2019-10-24","conditions":"Cryptococcal Meningitis","enrollment":178},{"nctId":"NCT04072640","phase":"EARLY_PHASE1","title":"Three Induction Treatments on Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-01-25","conditions":"Cryptococcal Meningitis, HIV/AIDS","enrollment":120},{"nctId":"NCT03112031","phase":"PHASE2","title":"Treatment With Tamoxifen in Cryptococcal Meningitis","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2017-10-10","conditions":"Meningitis Streptococcal, Hiv, Meningitis","enrollment":50},{"nctId":"NCT01740947","phase":"PHASE4","title":"Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?","status":"TERMINATED","sponsor":"H. Jaap Bonjer, PhD","startDate":"2013-01","conditions":"Colorectal Cancer","enrollment":485},{"nctId":"NCT00936910","phase":"PHASE4","title":"Antifungal Locks to Treat Fungal-related Central Line Infections","status":"COMPLETED","sponsor":"Bill McGhee","startDate":"2006-09","conditions":"Central Line Fungal Infections","enrollment":13},{"nctId":"NCT00145249","phase":"PHASE2","title":"Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-05","conditions":"Cryptococcal Meningitis","enrollment":143},{"nctId":"NCT00696969","phase":"PHASE3","title":"Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2008-06","conditions":"Visceral Leishmaniasis","enrollment":634},{"nctId":"NCT00012467","phase":"PHASE2","title":"Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis","status":"COMPLETED","sponsor":"InterMune","startDate":"2000-01","conditions":"Meningitis, Cryptococcal, HIV Infections","enrollment":60},{"nctId":"NCT00158730","phase":"PHASE3","title":"Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-04","conditions":"Invasive Aspergillosis, Other Fungal Infections","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"recentPublications":[{"date":"2018 Nov 23","pmid":"30470259","title":"AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.","journal":"Trials"},{"date":"2018 Dec","pmid":"30022696","title":"Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.","journal":"Current medical research and opinion"},{"date":"2016 Sep","pmid":"27075673","title":"Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.","journal":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"date":"2015 Jun 17","pmid":"26081985","title":"AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.","journal":"Trials"},{"date":"2013 Aug","pmid":"23474174","title":"How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["L-AmB conventional therapy"],"phase":"phase_3","status":"active","brandName":"L-AmB standard dose","genericName":"L-AmB standard dose","companyName":"Federal University of Health Science of Porto Alegre","companyId":"federal-university-of-health-science-of-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-AmB (liposomal amphotericin B) binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and lead to cell death. Used for Invasive fungal infections (candidiasis, aspergillosis, cryptococcosis), Empiric therapy for suspected fungal infections in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}